147 related articles for article (PubMed ID: 33878406)
1. Stimulant use in patients presenting with psychocutaneous disorders.
Richey PM; Laageide L; Swick BL
J Am Acad Dermatol; 2022 May; 86(5):1002-1009. PubMed ID: 33878406
[TBL] [Abstract][Full Text] [Related]
2. Adverse psychocutaneous effects of prescription stimulant use and abuse: A systematic review.
Moattari CR; França K
J Dtsch Dermatol Ges; 2022 Jan; 20(1):7-15. PubMed ID: 34990063
[TBL] [Abstract][Full Text] [Related]
3. Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation.
Sara GE; Large MM; Matheson SL; Burgess PM; Malhi GS; Whiteford HA; Hall WD
Aust N Z J Psychiatry; 2015 Feb; 49(2):106-17. PubMed ID: 25518844
[TBL] [Abstract][Full Text] [Related]
4. Stimulant use disorders: characteristics and comorbidity in an Australian population sample.
Sara G; Burgess P; Harris M; Malhi GS; Whiteford H; Hall W
Aust N Z J Psychiatry; 2012 Dec; 46(12):1173-81. PubMed ID: 22990432
[TBL] [Abstract][Full Text] [Related]
5. Needs assessment survey of psychocutaneous medicine.
Kawahara T; Henry L; Mostaghimi L
Int J Dermatol; 2009 Oct; 48(10):1066-70. PubMed ID: 19785088
[TBL] [Abstract][Full Text] [Related]
6. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
Faraone SV; Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
[TBL] [Abstract][Full Text] [Related]
7. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH
Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
[TBL] [Abstract][Full Text] [Related]
8. Risk of amphetamine use disorder and mortality among incident users of prescribed stimulant medications in the Veterans Administration.
Westover AN; Nakonezny PA; Halm EA; Adinoff B
Addiction; 2018 May; 113(5):857-867. PubMed ID: 29215762
[TBL] [Abstract][Full Text] [Related]
9. Self-managing illicit stimulant use: A qualitative study with patients receiving injectable opioid agonist treatment.
Palis H; Harrison S; MacDonald S; Marsh DC; Schechter MT; Oviedo-Joekes E
Drug Alcohol Rev; 2020 Nov; 39(7):914-923. PubMed ID: 32588514
[TBL] [Abstract][Full Text] [Related]
10. Psychocutaneous Medicine Clinic: Wisconsin Experience.
Mostaghimi L
J Acad Consult Liaison Psychiatry; 2021; 62(5):522-527. PubMed ID: 33975073
[TBL] [Abstract][Full Text] [Related]
11. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study.
Barkley RA; Fischer M; Smallish L; Fletcher K
Pediatrics; 2003 Jan; 111(1):97-109. PubMed ID: 12509561
[TBL] [Abstract][Full Text] [Related]
12. Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders.
Dela Cruz AM; Carmody T; Greer TL; Rethorst CD; Warden D; Walker R; Trivedi MH
Am J Addict; 2016 Apr; 25(3):215-20. PubMed ID: 26991889
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness.
McDonell MG; Srebnik D; Angelo F; McPherson S; Lowe JM; Sugar A; Short RA; Roll JM; Ries RK
Am J Psychiatry; 2013 Jan; 170(1):94-101. PubMed ID: 23138961
[TBL] [Abstract][Full Text] [Related]
14. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset.
DelBello MP; Soutullo CA; Hendricks W; Niemeier RT; McElroy SL; Strakowski SM
Bipolar Disord; 2001 Apr; 3(2):53-7. PubMed ID: 11333062
[TBL] [Abstract][Full Text] [Related]
15. Illicit use of prescribed stimulant medication among college students.
Hall KM; Irwin MM; Bowman KA; Frankenberger W; Jewett DC
J Am Coll Health; 2005; 53(4):167-74. PubMed ID: 15663065
[TBL] [Abstract][Full Text] [Related]
16. Stimulant Use Disorders.
Park TM; Haning WF
Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):461-71. PubMed ID: 27338967
[TBL] [Abstract][Full Text] [Related]
17. Does stimulant treatment lead to substance use disorders?
Faraone SV; Wilens T
J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
[TBL] [Abstract][Full Text] [Related]
18. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
[TBL] [Abstract][Full Text] [Related]
19. The impact of cigarette smoking on stimulant addiction.
Weinberger AH; Sofuoglu M
Am J Drug Alcohol Abuse; 2009; 35(1):12-7. PubMed ID: 19152200
[TBL] [Abstract][Full Text] [Related]
20. Psychodermatology: a guide to understanding common psychocutaneous disorders.
Jafferany M
Prim Care Companion J Clin Psychiatry; 2007; 9(3):203-13. PubMed ID: 17632653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
